Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo

作     者：Cyrille Mathieu Marion Ferren Olivia Harder Francesca TBovier Tara CMarcink Camilla Predella Fabrizio Angius Jennifer Drew-Bear NValerio Dorrello Alex LGreninger Anne Moscona Stefan Niewiesk Branka Horvat Matteo Porotto 

作者机构：Center for Host-Pathogen InteractionColumbia University Vagelos College of Physicians and SurgeonsNew YorkNYUSA Department of PediatricsColumbia University Vagelos College of Physicians and SurgeonsNew YorkNYUSA CIRICentre International de Recherche en InfectiologieTeam IBIVUniv LyonInsermU1111UniversitéClaude Bernard Lyon 1CNRSUMR5308ENS de LyonF-69007LyonFrance Department of Veterinary BiosciencesCollege of Veterinary MedicineThe Ohio State UniversityColumbusOHUSA epartment of Experimental MedicineUniversitàVanvitelliCasertaItaly Department of Laboratory MedicineUniversity of Washington School of MedicineSeattleWAUSA Vaccine and Infectious Disease DivisionFred Hutchinson Cancer Research CenterSeattleWAUSA Department of Microbiology&ImmunologyColumbia University Vagelos College of Physicians and SurgeonsNew YorkNYUSA Department of Physiology&Cellular BiophysicsColumbia University Vagelos College of Physicians and SurgeonsNew YorkNYUSA 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2021年第18卷第7期

页      面：1835-1837页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1001[医学-基础医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by grants from the NIH:All21349 NS091263 and NS105699 Al 146980 to M.P. from the French ANR NITRODEP(ANR-13-PDOC-OO10-01)to C.M.and from the Region Auvergne Rhone Alpes and LABEX ECOFECT(ANR-11-LABX-0048)of Lyon University within the program"Investissements d'Avenir"(ANR-11-IDEX-0007) operated by the French National Research Agency(ANR)to B.H.The Sharon Golub Fund at Columbia University Irving Medical Center(CUIMC). 

主　　题：neutral priori UNICEF 

摘      要：Despite the availability of an effective measles virus(MeV)vaccine and efforts to increase vaccine coverage by the WHO,UNICEF,and their partners,MeV has not been eradicated,and the estimated global measles death rose from 89,780 in 2016 to 207,500 in 2019.1 Because there is an effective measles vaccine,antiviral development for measles has not been prioritized,but recent outbreaks have highlighted the need for drugs to prevent transmission in unvaccinated populations and to protect and treat immunocompromised individuals.We identified several neutralizing mouse monoclonal antibodies(mAbs)that target the MeV fusion(F)protein in its prefusion state2 and inhibit fusion and viral infection.We engineered a single-chain variable fragment(scFv)from the most potent anti-MeV F mAb.The scFv retains the ability to inhibit fusion and prevents infection in vitro,and intranasal administration of the scFv antibody construct prevents infection in vivo.